» Articles » PMID: 15843472

Statins Prevent Oxidized LDL-induced Injury of Glomerular Podocytes by Activating the Phosphatidylinositol 3-kinase/AKT-signaling Pathway

Overview
Specialty Nephrology
Date 2005 Apr 22
PMID 15843472
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

The injury of podocytes is associated with alterations of the glomerular size-selective barrier to proteins. In this study, oxidized LDL (oxLDL) but not native LDL induced apoptosis in human cultured podocytes and reduced Akt activity and P-Akt/Akt ratio. Moreover, oxLDL-induced redistribution and loss of nephrin, an adhesion molecule specific for the glomerular slit diaphragm. Nephrin reduction was preceded by inhibition of nephrin tyrosine phosphorylation and of its association with p85 phosphatidylinositol 3-kinase (PI3K). Moreover, three different statins, mevastatin, pravastatin, and simvastatin, inhibited in a dose-dependent manner apoptosis and loss of nephrin induced by oxLDL by stimulating Akt activity. In addition, simvastatin significantly increased the expression of nephrin protein and mRNA by podocytes. The protective effects of statins were blocked by treatment of podocytes with two unrelated pharmacologic inhibitors of PI3K, LY294002 and wortmannin, suggesting a role for PI3K, and by mevalonate, indicating dependency on HMG-CoA reductase activity. Statins directly stimulated Akt phosphorylation ad activity. Finally, oxLDL induced a retraction of cultured podocytes and an increase in the albumin diffusion across their monolayer that was inhibited by treatment with statins. In conclusion, statins reduced the oxLDL-induced apoptosis and loss of nephrin in glomerular podocytes. The statin-induced Akt activation may protect from the loss of nephrin by an inhibition of its redistribution and shedding and by a stimulation of its synthesis. These data provide a rationale for the anti-proteinuric effect of statins.

Citing Articles

Metabolic Syndrome, Kidney-Related Adiposity, and Kidney Microcirculation: Unraveling the Damage.

Jang K, Hur J, Lee D, Kim S Biomedicines. 2025; 12(12.

PMID: 39767613 PMC: 11673429. DOI: 10.3390/biomedicines12122706.


Insulin Resistance, Obesity, and Lipotoxicity.

Yazici D, Demir S, Sezer H Adv Exp Med Biol. 2024; 1460:391-430.

PMID: 39287860 DOI: 10.1007/978-3-031-63657-8_14.


A non-linear association between low-density lipoprotein cholesterol and the risk of diabetic kidney disease in patients with type 2 diabetes in China.

Xiang X, Chen G, Ma Y, Wang H Prev Med Rep. 2024; 45:102840.

PMID: 39175593 PMC: 11339054. DOI: 10.1016/j.pmedr.2024.102840.


Lipid homeostasis in diabetic kidney disease.

Wang Y, Liu T, Wu Y, Wang L, Ding S, Hou B Int J Biol Sci. 2024; 20(10):3710-3724.

PMID: 39113692 PMC: 11302873. DOI: 10.7150/ijbs.95216.


Clinical characteristics and treatment compounds of obesity-related kidney injury.

Mao T, Huang H, Zhang C World J Diabetes. 2024; 15(6):1091-1110.

PMID: 38983811 PMC: 11229974. DOI: 10.4239/wjd.v15.i6.1091.